GlassScriptPhysician profile
Hector Anibal Ponce
NPI 1083485213
$2,216.78
in general payments reported to CMS, 2019-2025
17 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $727 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $523.87 | 2024-2025 | Krystexxa, Tavneos |
| Ardelyx, INC. | $416.10 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $388.15 | 2024-2025 | |
| Medtronic, INC. | $160.18 | 2025 | Ellipsys Vascular Access System |
| Glaxosmithkline, LLC. | $141.80 | 2024-2025 | Benlysta |
| Novo Nordisk INC | $104.22 | 2024-2025 | Wegovy, Ozempic |
| Otsuka America Pharmaceutical, INC. | $93.40 | 2024-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $74.22 | 2024 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.62 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $67.77 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $60.76 | 2024-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $24.80 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $21.14 | 2025 | Acthar |
| Scpharmaceuticals INC. | $20.94 | 2025 | |
| Lilly USA, LLC | $17.89 | 2024 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.99 | 2025 | Keveyis |
| Vifor Pharma, INC. | $13.93 | 2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Ponce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.